Periferakis A, Tsigas G, Periferakis A, Tone C, Hemes D, Periferakis K
Curr Issues Mol Biol. 2024; 46(9):9721-9759.
PMID: 39329930
PMC: 11430067.
DOI: 10.3390/cimb46090578.
Li J, You C, Li Y, Li C, Fan W, Chen Z
Proc Natl Acad Sci U S A. 2024; 121(26):e2321710121.
PMID: 38885377
PMC: 11214081.
DOI: 10.1073/pnas.2321710121.
Kumar U
Int J Mol Sci. 2024; 25(1).
PMID: 38203605
PMC: 10779198.
DOI: 10.3390/ijms25010436.
Patel B, Desai R, Pugazenthi S, Butt O, Huang J, Kim A
Front Oncol. 2022; 12:851758.
PMID: 35402234
PMC: 8984123.
DOI: 10.3389/fonc.2022.851758.
Behling F, Fodi C, Skardelly M, Renovanz M, Castaneda S, Tabatabai G
Neurosurg Rev. 2021; 45(1):467-478.
PMID: 33899156
PMC: 8827401.
DOI: 10.1007/s10143-021-01552-y.
DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.
Ben-Shlomo A, Deng N, Ding E, Yamamoto M, Mamelak A, Chesnokova V
J Clin Invest. 2020; 130(11):5738-5755.
PMID: 32673291
PMC: 7598090.
DOI: 10.1172/JCI138540.
Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity.
Kumar U, Singh S
Int J Mol Sci. 2020; 21(7).
PMID: 32272767
PMC: 7177963.
DOI: 10.3390/ijms21072568.
Ectopic cushing's syndrome caused by an 8 mm lung carcinoid localized by scintigram with the somatostatin analogin-pentetreotide.
Raposo J, Bugalho M, Sobrinho L, Pefeira M, Boavida J, Loureiro M
Endocr Pathol. 2020; 5(3):191-195.
PMID: 32138427
DOI: 10.1007/BF02921476.
The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity.
Larocca A, Toniolo G, Tortorella S, Krokidis M, Menounou G, Di Bella G
Molecules. 2019; 24(17).
PMID: 31450691
PMC: 6749267.
DOI: 10.3390/molecules24173085.
High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma.
Behling F, Honegger J, Skardelly M, Gepfner-Tuma I, Tabatabai G, Tatagiba M
Int J Endocrinol. 2019; 2018:1763735.
PMID: 30627156
PMC: 6304820.
DOI: 10.1155/2018/1763735.
Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki K, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas G
Biomed Res Int. 2018; 2017:9856140.
PMID: 29349087
PMC: 5733630.
DOI: 10.1155/2017/9856140.
Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.
Khan M, Huang T, Lin C, Wu J, Fan B, Bian Z
Oncotarget. 2017; 8(61):104615-104637.
PMID: 29262666
PMC: 5732832.
DOI: 10.18632/oncotarget.18403.
Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury.
Li X, Rao T, Xu Y, Hu K, Zhu Z, Li H
Acta Pharmacol Sin. 2017; 39(8):1373-1385.
PMID: 29188801
PMC: 6296301.
DOI: 10.1038/aps.2017.159.
The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?.
Guarnotta V, Martini C, Davi M, Pizza G, Colao A, Faggiano A
Endocrine. 2017; 60(1):15-27.
PMID: 29019150
DOI: 10.1007/s12020-017-1420-4.
Somatostatin analogues labeled with copper radioisotopes: current status.
Marciniak A, Brasun J
J Radioanal Nucl Chem. 2017; 313(2):279-289.
PMID: 28804185
PMC: 5533839.
DOI: 10.1007/s10967-017-5323-x.
Converting disulfide bridges in native peptides to stable methylene thioacetals.
Kourra C, Cramer N
Chem Sci. 2017; 7(12):7007-7012.
PMID: 28451136
PMC: 5355835.
DOI: 10.1039/c6sc02285e.
Clinical utility of lanreotide Autogel in gastroenteropancreatic neuroendocrine tumors.
Paragliola R, Prete A, Papi G, Torino F, Corsello A, Pontecorvi A
Drug Des Devel Ther. 2016; 10:3459-3470.
PMID: 27822010
PMC: 5087808.
DOI: 10.2147/DDDT.S76732.
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C, Rousaki P, Negri M, Sarnataro M, Napolitano M, Marino F
Endocrine. 2016; 56(3):603-620.
PMID: 27688013
DOI: 10.1007/s12020-016-1079-2.
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
Nonnekens J, van Kranenburg M, Beerens C, Suker M, Doukas M, van Eijck C
Theranostics. 2016; 6(11):1821-32.
PMID: 27570553
PMC: 4997239.
DOI: 10.7150/thno.15311.
(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
Chang C, Pattison D, Tothill R, Kong G, Akhurst T, Hicks R
Cancer Imaging. 2016; 16(1):22.
PMID: 27535829
PMC: 4989291.
DOI: 10.1186/s40644-016-0084-2.
